Vestmark Advisory Solutions Inc. Grows Position in DexCom, Inc. $DXCM

Key Points

• Vestmark Advisory Solutions Inc. increased its stake in DexCom by 369.9% in Q1, owning 15,172 shares worth $1.04 million after additional purchases.
• Recent analyst ratings show a mix of upgrades and target price changes, with a consensus target price of $99.89 and an average rating of "Moderate Buy" for DexCom shares.
• Insider trading activity included 500 shares sold by EVP Michael Jon Brown, and a 28,656 share divestment by insiders in total over the past quarter.

Vestmark Advisory Solutions Inc. boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 369.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,172 shares of the medical device company's stock after buying an additional 11,943 shares during the quarter. Vestmark Advisory Solutions Inc.'s holdings in DexCom were worth $1,036,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Golden State Wealth Management LLC lifted its holdings in DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after buying an additional 264 shares in the last quarter. Zions Bancorporation National Association UT acquired a new stake in shares of DexCom in the 1st quarter valued at $27,000. Optiver Holding B.V. acquired a new stake in shares of DexCom in the 4th quarter valued at $33,000. Heck Capital Advisors LLC acquired a new stake in shares of DexCom in the 4th quarter valued at $38,000. Finally, Alpine Bank Wealth Management acquired a new stake in shares of DexCom in the 1st quarter valued at $40,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Performance

Shares of NASDAQ:DXCM traded up $0.7640 during midday trading on Friday, hitting $81.3840. The stock had a trading volume of 646,997 shares, compared to its average volume of 3,858,427. The company has a market capitalization of $31.91 billion, a PE ratio of 56.55, a P/E/G ratio of 1.71 and a beta of 1.43. The stock has a 50 day moving average price of $82.81 and a two-hundred day moving average price of $79.93. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business's quarterly revenue was up 15.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. As a group, equities analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. The Goldman Sachs Group assumed coverage on shares of DexCom in a research note on Friday, May 30th. They set a "buy" rating and a $104.00 price target on the stock. Wall Street Zen lowered shares of DexCom from a "strong-buy" rating to a "buy" rating in a research note on Sunday, August 10th. Canaccord Genuity Group reiterated a "buy" rating and set a $106.00 price target on shares of DexCom in a research note on Friday, August 1st. Citigroup reiterated a "buy" rating and set a $102.00 price target (up from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Finally, Argus assumed coverage on shares of DexCom in a research note on Thursday. They set a "buy" rating and a $100.00 price target on the stock. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $99.90.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $88.99, for a total transaction of $130,459.34. Following the completion of the transaction, the executive vice president owned 106,689 shares in the company, valued at approximately $9,494,254.11. The trade was a 1.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the transaction, the director owned 51,121 shares of the company's stock, valued at approximately $4,143,868.26. The trade was a 5.10% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 21,906 shares of company stock worth $1,832,451 in the last ninety days. Corporate insiders own 0.32% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.